ACRIVON THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.72 USD | -2.89% |
|
-9.71% | +56.91% |
| 14/05 | Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 30/04 | North American Morning Briefing : More Earnings -2- | DJ |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 240.6 | 109.2 | 245.5 | - | - |
| Enterprise Value (EV) 1 | 112.8 | 109.2 | 245.5 | 245.5 | 245.5 |
| P/E ratio | -1.52 x | -1.8 x | -3.12 x | -2.81 x | -2.7 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 243 x | 11.9 x |
| EV / Revenue | - | - | - | 243 x | 11.9 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | -7.45 x | - | -3.52 x | -3.04 x | -2.27 x |
| FCF Yield | -13.4% | - | -28.4% | -32.9% | -44% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 20,885 | 22,194 | 30,877 | - | - |
| Reference price 2 | 11.52 | 4.920 | 7.720 | 7.720 | 7.720 |
| Announcement Date | 28/03/23 | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 1.009 | 20.68 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -32.66 | -67.1 | -80.15 | -106.7 | -114.1 |
| Operating Margin | - | - | - | - | -10,570.31% | -551.83% |
| Earnings before Tax (EBT) 1 | - | -31.17 | -60.39 | -77.6 | -103.2 | -112.4 |
| Net income 1 | -16.24 | -31.17 | -60.39 | -77.6 | -103.2 | -112.4 |
| Net margin | - | - | - | - | -10,225.45% | -543.68% |
| EPS 2 | -3.780 | -7.560 | -2.740 | -2.474 | -2.747 | -2.859 |
| Free Cash Flow 1 | - | -32.28 | - | -69.83 | -80.65 | -108.1 |
| FCF margin | - | - | - | - | -7,991.26% | -522.8% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 12/08/22 | 28/03/23 | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -9.575 | -9.945 | -14.39 | -15.52 | -16.14 | -21.05 | -17.67 | -20.35 | -20.65 | -21.07 | -23.5 | -24 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -9.198 | -8.929 | -12.76 | -13.91 | -14.47 | -19.25 | -16.49 | -20.21 | -21.07 | -21.84 | -23.5 | -24 |
| Net income 1 | -9.198 | -8.929 | -12.76 | -13.91 | -14.47 | -19.25 | -16.49 | -20.21 | -21.07 | -21.84 | -23.5 | -24 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -5.170 | -0.8000 | -0.5800 | -0.6300 | -0.6600 | -0.8700 | -0.7300 | -0.5914 | -0.5600 | -0.5614 | -0.6400 | -0.6650 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 15/12/22 | 28/03/23 | 09/05/23 | 11/08/23 | 09/11/23 | 28/03/24 | 14/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | 128 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -32.3 | - | -69.8 | -80.6 | -108 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 2.17 | - | 1.39 | 0.98 | 1.12 |
| Capex / Sales | - | - | - | - | 96.66% | 5.43% |
| Announcement Date | 12/08/22 | 28/03/23 | 28/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
7.72
USD
Average target price
22.12
USD
Spread / Average Target
+186.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +56.91% | 25Cr | |
| +54.05% | 6.39TCr | |
| -2.02% | 4.18TCr | |
| +40.01% | 4.05TCr | |
| -10.22% | 2.72TCr | |
| +13.42% | 2.65TCr | |
| -21.60% | 1.87TCr | |
| +2.89% | 1.27TCr | |
| +22.40% | 1.21TCr | |
| +27.49% | 1.21TCr |
- Stock Market
- Equities
- ACRV Stock
- Financials Acrivon Therapeutics, Inc.
